OZOPROMAF_SEQ1

Small molecule

UUniversity of Palermo

OZOPROMAF_SEQ1 is one of 18 small molecule programs targeting Osteonecrosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

OsteonecrosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Osteonecrosis

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

2 2

Bayer Aspirin

Bayer

Phase 3

1 3

Antibiotics

MMelinta Therapeutics, Inc.

Approved

1 4

Trental

VValidus Pharmaceuticals

Phase 3

1 5

Boniva

CConrado Roberto Hoffmann Filho

Phase 3

1 6

Zometa

Pfizer

Phase 2

5 7

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—8

Tocopherol

MM.D. Anderson Cancer Center

Phase 3

1 9

Ixmyelocel-T

VVericel Corporation

Phase 3

1 10

Ibandronate IV

NNational Taiwan University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteonecrosis1 trial

Infiltration of Medical Ozone for the Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ)

Suspended·UUniversity of Palermo·Phase 1/2·NCT05036837·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OZOPROMAF_SEQ1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OZOPROMAF_SEQ1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OZOPROMAF_SEQ1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Palermo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Palermo

OZOPROMAF_SEQ1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteonecrosis1 trial

References

Drug Info

Quick Facts

Related News